Abstracts by key term: Fibrosis staging
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a growing healthcare challenge, closely linked to metabolic syndrome. It manifests in a range of forms, from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis. The revised nomenclature better reflects the role of metabolic disorders. The pathophysiology is complex, characterized by metabolic risk factors, lipotoxicity, and inflammatory processes. Advances in research emphasize the importance of mitochondrial function and immune responses. Noninvasive diagnostic methods are prioritized to minimize risks and costs. Imaging techniques and serum-based scores support the assessment of fibrosis stages. Treatment focuses on lifestyle changes, particularly weight reduction and physical activity. Pharmacological interventions are still being investigated, with promising approaches in clinical trials. The high prevalence of MASLD in diabetes patients and its association with severe complications underscore the urgency of effective diagnostic and treatment strategies. Future research and innovative therapies are crucial to improving the prognosis for those affected and reducing the burden of disease.